Skip to content
AnalystLens

ECOLAB INC. Quarterly Report for Q2 Ended Jun 30, 2004

Filing Date
Filed August 6, 2004
Period End
June 30, 2004
Security
ECL
In the record · 2016–202610-K1110-Q328-K144

ECL filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 144 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Sep ’16Sep ’16
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Deal closed8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Aug ’25Aug ’25

Summary

Summary of the 10-Q filed August 6, 2004. Cited figures are marked; the original filing is the authoritative source.

Ecolab Inc. reported strong financial performance for the second quarter and first six months of 2004.

Net sales increased by 10%a and 11% respectively compared to the prior year periods, driven by robust growth in both U.S. and International Cleaning & Sanitizing operations. Diluted net income per share saw a significant 20% increase, reflecting improved operational efficiencies, favorable currency movements, and a lower effective tax rate. The company also demonstrated strong operating cash flow, enabling continued investment in growth initiatives, including strategic acquisitions like Nigiko, Daydots International, and Elimco.

These acquisitions, while not individually material, contribute to the company's overall expansion. Financially, Ecolab maintained a solid balance sheet with total assets growing by 6% to $3.41 billionb. While total debt saw a slight increase, the debt-to-capitalization ratio remained stable at 34%, indicating strong financial management.

The company repurchased shares and paid dividends, demonstrating a commitment to shareholder returns. Subsequent to the quarter, Ecolab completed the acquisition of Alcide Corporation, further strengthening its position in the biocidal and sanitation products market. The company anticipates benefits from the Medicare Prescription Drug, Improvement and Modernization Act of 2003, projecting an annual after-tax benefit of $1.5 to $2.0 millionc.

Key Highlights

  1. Consolidated net sales increased by 10% to $1.04 billion in Q2 2004 and 11% to $2.02 billion for the first six months of 2004.
  2. Diluted net income per share rose 20% to $0.30 in Q2 2004 and to $0.55 for the first six months, up from $0.25 and $0.46 respectively in the prior year.
  3. Gross profit margin improved to 51.6% in Q2 2004 and for the year-to-date period, up from 50.7% and 50.8% in the prior year, attributed to improved business mix and cost savings.
  4. Operating income for International Cleaning & Sanitizing operations increased 12% in Q2 and 13% for the six-month period.
  5. The company completed several strategic acquisitions during the quarter, including Nigiko, Daydots International, and Elimco, and subsequently acquired Alcide Corporation post-quarter end.
  6. Cash provided by operating activities was strong, totaling $233 million for the first six months of 2004.
  7. Effective income tax rate decreased from 38.9% to 37.2% for the first six months of 2004, benefiting net income.

Frequently Asked Questions

  1. What were the primary drivers of Ecolab's sales growth in the second quarter of 2004?

    Sales growth was driven by a 5% increase in U.S. Cleaning & Sanitizing operations, with notable strength in Kay sales (up 16%) and accelerating Food & Beverage sales growth (up 6%). International Cleaning & Sanitizing operations also saw an 8% increase at fixed currency rates, despite slower growth in Europe and Asia Pacific. Overall, improving market conditions, successful new product introductions, and strategic acquisitions contributed to the sales performance.

  2. How did Ecolab's profitability change in the reported periods?

    Profitability improved significantly. Diluted net income per share increased by 20% year-over-year for both the second quarter and the six-month period. This was supported by a higher gross profit margin (51.6% in Q2 2004), operational improvements, favorable currency translation effects, and a lower effective income tax rate.

  3. What is the impact of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 on Ecolab?

    Ecolab expects to benefit from the Act, particularly regarding its U.S. Postretirement Health Care Benefits plan, which offers prescription drug benefits. The company estimates an annual after-tax benefit in the range of $1.5 to $2.0 million starting in the third quarter of 2004, as it begins recording these favorable effects.

  4. What significant corporate actions or events occurred around the reporting period?

    During the second quarter, Ecolab completed several acquisitions, including Nigiko, Daydots International, and Elimco. Notably, subsequent to the quarter on July 30, 2004, Ecolab closed on the purchase of Alcide Corporation. The company also continued its share repurchase program, buying back 225,001 shares during the second quarter.